1. Home
  2. MPV vs PBYI Comparison

MPV vs PBYI Comparison

Compare MPV & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Participation Investors

MPV

Barings Participation Investors

HOLD

Current Price

$17.04

Market Cap

169.4M

Sector

Finance

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$9.57

Market Cap

467.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPV
PBYI
Founded
1988
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.4M
467.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
MPV
PBYI
Price
$17.04
$9.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.4K
265.6K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.71%
N/A
EPS Growth
N/A
N/A
EPS
1.71
0.08
Revenue
N/A
$27,685,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.99
$119.00
Revenue Growth
N/A
N/A
52 Week Low
$15.05
$4.37
52 Week High
$20.58
$9.74

Technical Indicators

Market Signals
Indicator
MPV
PBYI
Relative Strength Index (RSI) 57.48 60.95
Support Level $16.05 $7.56
Resistance Level $17.38 N/A
Average True Range (ATR) 0.33 0.35
MACD 0.02 -0.02
Stochastic Oscillator 83.87 83.77

Price Performance

Historical Comparison
MPV
PBYI

About MPV Barings Participation Investors

Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: